• Profile
Close

Antibody-based ticagrelor reversal agent in healthy volunteers

New England Journal of Medicine Mar 22, 2019

Bhatt DL, et al. - In this randomized, double-blind, placebo-controlled, phase 1 trial, researchers tested the premise that PB2452, a monoclonal antibody fragment that binds ticagrelor with high affinity, could be used to rapidly reverse the antiplatelet effects of ticagrelor (an oral P2Y12 inhibitor), reducing the risk or severity of bleeding. Of the 64 randomized volunteers, 48 were assigned to receive PB2452 and 16 were assigned to receive placebo. According to findings, the administration of PB2452 in healthy volunteers provided immediate and sustained reversal of the antiplatelet effects of ticagrelor, as assessed by multiple assays. Adverse drug-related events were mainly issues having to do with the site of infusion.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay